Compare Inovio Pharmaceuticals Inc (INO) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Microsoft — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while Microsoft trades at $397.54 (market cap $2.99T). The key difference: Microsoft is far larger — about 33493.9× Inovio Pharmaceuticals Inc's market cap, and Microsoft pays a 0.9% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | MSFT | |
|---|---|---|
Market Cap | $89.27M | $2.99T |
Sector | Health | Technology |
52-Week High | $2.87 | $542.07 |
52-Week Low | $1.05 | $352.83 |
Enterprise Value | $60.28M | $2.97T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Microsoft (MSFT) trades at $397.74, up 1.0% today, with a bullish technical signal and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.27 exceeding the $4.06 estimate. Revenue grew to $281.72B in 2025, with a net income margin of 39.34%. Analyst sentiment is overwhelmingly positive, with 80.49% buy ratings and a consensus price target of $546.70. Recent news highlights AI leadership and Azure momentum, though concerns over capital expenditures persist.
The outlook for MSFT remains favorable, driven by AI integration and cloud growth, but risks include competitive pressures and macroeconomic volatility. With a P/E of 23.96, the valuation is reasonable given robust profitability. Institutional confidence is high, supporting potential upside toward the $546.70 target, though investors should monitor execution on AI investments and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
